S&P 500   3,384.40 (+0.64%)
DOW   27,906.44 (+0.45%)
QQQ   280.85 (+1.08%)
AAPL   116.62 (+0.70%)
MSFT   212.16 (+0.87%)
FB   266.04 (+1.58%)
GOOGL   1,485.87 (+1.38%)
AMZN   3,189.69 (+1.30%)
TSLA   438.98 (+2.32%)
NVDA   541.52 (+0.06%)
BABA   291.17 (-0.96%)
CGC   14.23 (-0.63%)
MU   47.56 (+1.28%)
GE   6.17 (-0.96%)
AMD   83.42 (+1.74%)
T   28.58 (+0.25%)
F   6.74 (+1.20%)
ACB   4.70 (+1.08%)
GILD   62.86 (-0.52%)
NFLX   506.04 (+1.20%)
DIS   124.20 (+0.10%)
BA   170.08 (+2.92%)
BAC   24.10 (+0.04%)
S&P 500   3,384.40 (+0.64%)
DOW   27,906.44 (+0.45%)
QQQ   280.85 (+1.08%)
AAPL   116.62 (+0.70%)
MSFT   212.16 (+0.87%)
FB   266.04 (+1.58%)
GOOGL   1,485.87 (+1.38%)
AMZN   3,189.69 (+1.30%)
TSLA   438.98 (+2.32%)
NVDA   541.52 (+0.06%)
BABA   291.17 (-0.96%)
CGC   14.23 (-0.63%)
MU   47.56 (+1.28%)
GE   6.17 (-0.96%)
AMD   83.42 (+1.74%)
T   28.58 (+0.25%)
F   6.74 (+1.20%)
ACB   4.70 (+1.08%)
GILD   62.86 (-0.52%)
NFLX   506.04 (+1.20%)
DIS   124.20 (+0.10%)
BA   170.08 (+2.92%)
BAC   24.10 (+0.04%)
S&P 500   3,384.40 (+0.64%)
DOW   27,906.44 (+0.45%)
QQQ   280.85 (+1.08%)
AAPL   116.62 (+0.70%)
MSFT   212.16 (+0.87%)
FB   266.04 (+1.58%)
GOOGL   1,485.87 (+1.38%)
AMZN   3,189.69 (+1.30%)
TSLA   438.98 (+2.32%)
NVDA   541.52 (+0.06%)
BABA   291.17 (-0.96%)
CGC   14.23 (-0.63%)
MU   47.56 (+1.28%)
GE   6.17 (-0.96%)
AMD   83.42 (+1.74%)
T   28.58 (+0.25%)
F   6.74 (+1.20%)
ACB   4.70 (+1.08%)
GILD   62.86 (-0.52%)
NFLX   506.04 (+1.20%)
DIS   124.20 (+0.10%)
BA   170.08 (+2.92%)
BAC   24.10 (+0.04%)
S&P 500   3,384.40 (+0.64%)
DOW   27,906.44 (+0.45%)
QQQ   280.85 (+1.08%)
AAPL   116.62 (+0.70%)
MSFT   212.16 (+0.87%)
FB   266.04 (+1.58%)
GOOGL   1,485.87 (+1.38%)
AMZN   3,189.69 (+1.30%)
TSLA   438.98 (+2.32%)
NVDA   541.52 (+0.06%)
BABA   291.17 (-0.96%)
CGC   14.23 (-0.63%)
MU   47.56 (+1.28%)
GE   6.17 (-0.96%)
AMD   83.42 (+1.74%)
T   28.58 (+0.25%)
F   6.74 (+1.20%)
ACB   4.70 (+1.08%)
GILD   62.86 (-0.52%)
NFLX   506.04 (+1.20%)
DIS   124.20 (+0.10%)
BA   170.08 (+2.92%)
BAC   24.10 (+0.04%)
Log in
NASDAQ:LMNX

Luminex Stock Forecast, Price & News

$26.11
-0.14 (-0.53 %)
(As of 10/1/2020 11:32 AM ET)
Add
Compare
Today's Range
$25.91
Now: $26.11
$26.45
50-Day Range
$24.03
MA: $27.06
$32.20
52-Week Range
$17.34
Now: $26.11
$41.69
Volume3,309 shs
Average Volume652,140 shs
Market Capitalization$1.21 billion
P/E Ratio113.53
Dividend Yield1.37%
Beta0.58
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
Read More
Luminex logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.0Dividend Strength: 0.8Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:LMNX
CUSIP55027E10
Phone512-219-8020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$334.64 million
Cash Flow$0.45 per share
Book Value$10.32 per share

Profitability

Net Income$-3,840,000.00

Miscellaneous

Employees1,247
Market Cap$1.21 billion
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$26.11
-0.14 (-0.53 %)
(As of 10/1/2020 11:32 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LMNX News and Ratings via Email

Sign-up to receive the latest news and ratings for LMNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Luminex (NASDAQ:LMNX) Frequently Asked Questions

How has Luminex's stock been impacted by COVID-19 (Coronavirus)?

Luminex's stock was trading at $27.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LMNX stock has decreased by 3.7% and is now trading at $26.11.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Luminex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Luminex
.

When is Luminex's next earnings date?

Luminex is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Luminex
.

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) issued its quarterly earnings results on Tuesday, August, 4th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.19. The medical instruments supplier had revenue of $109.52 million for the quarter, compared to the consensus estimate of $107.33 million. Luminex had a net margin of 3.04% and a return on equity of 2.38%. The company's revenue was up 31.9% on a year-over-year basis. During the same period last year, the company earned ($0.11) EPS.
View Luminex's earnings history
.

How often does Luminex pay dividends? What is the dividend yield for Luminex?

Luminex announced a quarterly dividend on Wednesday, September 16th. Shareholders of record on Thursday, September 24th will be paid a dividend of $0.09 per share on Thursday, October 15th. This represents a $0.36 dividend on an annualized basis and a yield of 1.38%. The ex-dividend date of this dividend is Wednesday, September 23rd.
View Luminex's dividend history
.

What guidance has Luminex issued on next quarter's earnings?

Luminex issued an update on its third quarter 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $100 million, compared to the consensus revenue estimate of $89.47 million.

What price target have analysts set for LMNX?

2 Wall Street analysts have issued 12-month target prices for Luminex's shares. Their forecasts range from $32.00 to $38.00. On average, they expect Luminex's share price to reach $35.00 in the next year. This suggests a possible upside of 34.0% from the stock's current price.
View analysts' price targets for Luminex
.

Who are some of Luminex's key competitors?

What other stocks do shareholders of Luminex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include NVIDIA (NVDA), Baidu (BIDU), Cisco Systems (CSCO), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Square (SQ), Marvell Technology Group (MRVL), Micron Technology (MU), AbbVie (ABBV) and Crispr Therapeutics (CRSP).

Who are Luminex's key executives?

Luminex's management team includes the following people:
  • Mr. Nachum Shamir, CEO, Pres & Director (Age 65)
  • Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 57)
  • Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 51)
  • Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 49)
  • Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 57)

What is Luminex's stock symbol?

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

How do I buy shares of Luminex?

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Luminex's stock price today?

One share of LMNX stock can currently be purchased for approximately $26.11.

How big of a company is Luminex?

Luminex has a market capitalization of $1.21 billion and generates $334.64 million in revenue each year. The medical instruments supplier earns $-3,840,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Luminex employs 1,247 workers across the globe.

What is Luminex's official website?

The official website for Luminex is www.luminexcorp.com.

How can I contact Luminex?

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.